Tina Jordan
Family · McDonough, GANPI 1255703088
Payments from drug & device makers
Across 320 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$1K
- Biohaven Pharmaceuticals, Inc.$902
- Lilly USA, LLC$704
- Bayer$563
- AstraZeneca$482
- plus $2K from 24 others
What the payments were for
- Consulting fees$80011%
- Food & beverage$6,46689%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 66 | $1,592 |
| AbbVie | 58 | $1,061 |
| Biohaven Pharmaceuticals, Inc. | 9 | $902 |
| Lilly USA, LLC | 40 | $704 |
| Bayer | 21 | $563 |
| AstraZeneca | 15 | $482 |
| GSK | 15 | $395 |
| Amgen | 20 | $285 |
| Pfizer | 17 | $224 |
| Shield Therapeutics Inc | 8 | $160 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $158 |
| Amarin Pharma, Inc. | 5 | $96 |
| Kowa Pharmaceuticals America, Inc. | 5 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $75 |
| Novartis | 3 | $62 |
| Boehringer Ingelheim | 3 | $56 |
| Corcept Therapeutics | 2 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Stryker | 1 | $26 |
| Phadia US Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Exact Sciences | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Merck | 1 | $17 |
| Linus Health, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
- VRAYLAR$357
- Kerendia$250
- Saxenda$230
- Wegovy$228
- TRELEGY ELLIPTA$125
- FARXIGA$125
- AIRSUPRA$125
- Ozempic$125
- RYBELSUS$123
How this compares
$7,266 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $60,753 |
| LinzessLinaclotide | 38 | $49,412 |
| KerendiaFinerenone | 29 | $35,409 |
| MounjaroTirzepatide | 29 | $34,668 |
| TrulicityDulaglutide | 19 | $33,760 |
| JardianceEmpagliflozin | 35 | $30,782 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $22,791 |
| RybelsusSemaglutide | 11 | $21,393 |
| FarxigaDapagliflozin Propanediol | 13 | $18,245 |
| AmitizaLubiprostone | 13 | $4,319 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,983 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,641 |
| Colchicine | 11 | $1,127 |
| Rosuvastatin Calcium | 66 | $1,081 |
| Levothyroxine Sodium | 66 | $595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,592 | $82,14652 claims |
| Lilly USA, LLCMounjaro, Trulicity | $704 | $68,42848 claims |
| AbbVieLinzess | $1,061 | $49,41238 claims |
| BayerKerendia | $563 | $35,40929 claims |
| Boehringer IngelheimJardiance | $56 | $30,78235 claims |
| GSKTrelegy Ellipta | $395 | $22,79125 claims |
| AstraZenecaFarxiga, Symbicort | $482 | $21,22725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in McDonough
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.